Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Imugene Limited
Scientific Title
An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1 Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer